BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) traded up 6.8% on Monday . The stock traded as high as $2.55 and last traded at $2.53, with a volume of 120,595 shares. The stock had previously closed at $2.37.

Separately, Maxim Group reiterated a “buy” rating and issued a $5.00 price target on shares of BrainStorm Cell Therapeutics in a report on Monday, July 18th.

The firm’s market cap is $45.52 million. The firm has a 50 day moving average of $2.53 and a 200 day moving average of $2.42.

BrainStorm Cell Therapeutics (NASDAQ:BCLI) last posted its earnings results on Thursday, August 11th. The biotechnology company reported ($0.05) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.13. Analysts anticipate that BrainStorm Cell Therapeutics Inc. will post ($0.34) EPS for the current year.

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.